Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Alecensa (alectinib)
i
Other names:
CH5424802, RG7853, AF802, RO5424802, AF-802
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(104)
News
Trials
Company:
Roche
Drug class:
ALK inhibitor
Related drugs:
‹
crizotinib (312)
entrectinib (178)
lorlatinib (94)
ceritinib (67)
brigatinib (50)
ensartinib (42)
repotrectinib (27)
iruplinalkib (11)
TAE-684 (9)
SAF-189 (7)
TQ-B3101 (6)
APG-2449 (4)
TPX-0131 (4)
TGRX-326 (3)
TQ-B3139 (3)
AZD3463 (2)
SY-707 (1)
SY-3505 (1)
ALK inhibitor (0)
ASP-3026 (0)
CEP-37440 (0)
NVL-655 (0)
TY-2136b (0)
XZP-3621 (0)
ZG0418 (0)
TSR-011 (0)
crizotinib (312)
entrectinib (178)
lorlatinib (94)
ceritinib (67)
brigatinib (50)
ensartinib (42)
repotrectinib (27)
iruplinalkib (11)
TAE-684 (9)
SAF-189 (7)
TQ-B3101 (6)
APG-2449 (4)
TPX-0131 (4)
TGRX-326 (3)
TQ-B3139 (3)
AZD3463 (2)
SY-707 (1)
SY-3505 (1)
ALK inhibitor (0)
ASP-3026 (0)
CEP-37440 (0)
NVL-655 (0)
TY-2136b (0)
XZP-3621 (0)
ZG0418 (0)
TSR-011 (0)
›
Associations
(104)
News
Trials
VERI cancer hierarchy
Reset Filters
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
alectinib
Sensitive: A1 - Approval
FDA - 1 week (New A1)
alectinib
Sensitive
:
A1
FDA - 1wk
alectinib
Sensitive: A1 - Approval
FDA - 1 week
alectinib
Sensitive
:
A1
FDA - 1 week - (New A1)
ALK rearrangement
Non Small Cell Lung Cancer
ALK rearrangement
Non Small Cell Lung Cancer
alectinib
Sensitive: A2 - Guideline
alectinib
Sensitive
:
A2
alectinib
Sensitive: A2 - Guideline
alectinib
Sensitive
:
A2
ALK positive
Non-Hodgkin’s Lymphoma
ALK positive
Non-Hodgkin’s Lymphoma
alectinib
Sensitive: A2 - Guideline
alectinib
Sensitive
:
A2
alectinib
Sensitive: A2 - Guideline
alectinib
Sensitive
:
A2
ALK fusion
Lung Non-Squamous Non-Small Cell Cancer
ALK fusion
Lung Non-Squamous Non-Small Cell Cancer
alectinib
Sensitive: A2 - Guideline
alectinib
Sensitive
:
A2
alectinib
Sensitive: A2 - Guideline
alectinib
Sensitive
:
A2
ALK positive
Peripheral T-cell Lymphoma
ALK positive
Peripheral T-cell Lymphoma
alectinib
Sensitive: A2 - Guideline
alectinib
Sensitive
:
A2
alectinib
Sensitive: A2 - Guideline
alectinib
Sensitive
:
A2
ALK positive
Neuroendocrine Tumor
ALK positive
Neuroendocrine Tumor
alectinib
Sensitive: C1 - Off-label
alectinib
Sensitive
:
C1
alectinib
Sensitive: C1 - Off-label
alectinib
Sensitive
:
C1
ALK fusion
Non Small Cell Lung Cancer
ALK fusion
Non Small Cell Lung Cancer
alectinib
Sensitive: C2 – Inclusion Criteria
alectinib
Sensitive
:
C2
alectinib
Sensitive: C2 – Inclusion Criteria
alectinib
Sensitive
:
C2
RET rearrangement
Non Small Cell Lung Cancer
RET rearrangement
Non Small Cell Lung Cancer
alectinib
Sensitive: C2 – Inclusion Criteria
alectinib
Sensitive
:
C2
alectinib
Sensitive: C2 – Inclusion Criteria
alectinib
Sensitive
:
C2
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
atezolizumab + alectinib
Sensitive: C2 – Inclusion Criteria
atezolizumab + alectinib
Sensitive
:
C2
atezolizumab + alectinib
Sensitive: C2 – Inclusion Criteria
atezolizumab + alectinib
Sensitive
:
C2
ALK rearrangement
Solid Tumor
ALK rearrangement
Solid Tumor
alectinib
Sensitive: C2 – Inclusion Criteria
alectinib
Sensitive
:
C2
alectinib
Sensitive: C2 – Inclusion Criteria
alectinib
Sensitive
:
C2
ALK mutation
Non Small Cell Lung Cancer
ALK mutation
Non Small Cell Lung Cancer
alectinib
Sensitive: C2 – Inclusion Criteria
alectinib
Sensitive
:
C2
alectinib
Sensitive: C2 – Inclusion Criteria
alectinib
Sensitive
:
C2
ALK rearrangement
Non Small Cell Lung Cancer
ALK rearrangement
Non Small Cell Lung Cancer
bevacizumab + alectinib
Sensitive: C2 – Inclusion Criteria
bevacizumab + alectinib
Sensitive
:
C2
bevacizumab + alectinib
Sensitive: C2 – Inclusion Criteria
bevacizumab + alectinib
Sensitive
:
C2
ALK positive
Lung Non-Squamous Non-Small Cell Cancer
ALK positive
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + alectinib
Sensitive: C2 – Inclusion Criteria
bevacizumab + alectinib
Sensitive
:
C2
bevacizumab + alectinib
Sensitive: C2 – Inclusion Criteria
bevacizumab + alectinib
Sensitive
:
C2
ALK fusion
Lung Adenocarcinoma
ALK fusion
Lung Adenocarcinoma
alectinib
Sensitive: C2 – Inclusion Criteria
alectinib
Sensitive
:
C2
alectinib
Sensitive: C2 – Inclusion Criteria
alectinib
Sensitive
:
C2
ALK G1202R
Non Small Cell Lung Cancer
ALK G1202R
Non Small Cell Lung Cancer
alectinib
Resistant: C3 – Early Trials
alectinib
Resistant
:
C3
alectinib
Resistant: C3 – Early Trials
alectinib
Resistant
:
C3
ALK-HIP1 fusion
Non Small Cell Lung Cancer
ALK-HIP1 fusion
Non Small Cell Lung Cancer
alectinib
Sensitive: C3 – Early Trials
alectinib
Sensitive
:
C3
alectinib
Sensitive: C3 – Early Trials
alectinib
Sensitive
:
C3
ALK G1269A
Non Small Cell Lung Cancer
ALK G1269A
Non Small Cell Lung Cancer
alectinib
Sensitive: C3 – Early Trials
alectinib
Sensitive
:
C3
alectinib
Sensitive: C3 – Early Trials
alectinib
Sensitive
:
C3
ALK rearrangement + TP53 mutation
Non Small Cell Lung Cancer
ALK rearrangement + TP53 mutation
Non Small Cell Lung Cancer
alectinib
Resistant: C3 – Early Trials
alectinib
Resistant
:
C3
alectinib
Resistant: C3 – Early Trials
alectinib
Resistant
:
C3
ALK R1231W
Non Small Cell Lung Cancer
ALK R1231W
Non Small Cell Lung Cancer
alectinib
Sensitive: C3 – Early Trials
alectinib
Sensitive
:
C3
alectinib
Sensitive: C3 – Early Trials
alectinib
Sensitive
:
C3
ALK I1171S
Non Small Cell Lung Cancer
ALK I1171S
Non Small Cell Lung Cancer
alectinib
Resistant: C3 – Early Trials
alectinib
Resistant
:
C3
alectinib
Resistant: C3 – Early Trials
alectinib
Resistant
:
C3
ALK L1196M
Non Small Cell Lung Cancer
ALK L1196M
Non Small Cell Lung Cancer
alectinib
Sensitive: C3 – Early Trials
alectinib
Sensitive
:
C3
alectinib
Sensitive: C3 – Early Trials
alectinib
Sensitive
:
C3
ALK G1128A
Non Small Cell Lung Cancer
ALK G1128A
Non Small Cell Lung Cancer
alectinib
Sensitive: C3 – Early Trials
alectinib
Sensitive
:
C3
alectinib
Sensitive: C3 – Early Trials
alectinib
Sensitive
:
C3
ALK I1171N
Non Small Cell Lung Cancer
ALK I1171N
Non Small Cell Lung Cancer
alectinib
Resistant: C3 – Early Trials
alectinib
Resistant
:
C3
alectinib
Resistant: C3 – Early Trials
alectinib
Resistant
:
C3
ALK F1174V
Non Small Cell Lung Cancer
ALK F1174V
Non Small Cell Lung Cancer
alectinib
Sensitive: C3 – Early Trials
alectinib
Sensitive
:
C3
alectinib
Sensitive: C3 – Early Trials
alectinib
Sensitive
:
C3
ALK S1157F
Non Small Cell Lung Cancer
ALK S1157F
Non Small Cell Lung Cancer
alectinib
Sensitive: C3 – Early Trials
alectinib
Sensitive
:
C3
alectinib
Sensitive: C3 – Early Trials
alectinib
Sensitive
:
C3
ALK C1156F
Non Small Cell Lung Cancer
ALK C1156F
Non Small Cell Lung Cancer
alectinib
Sensitive: C3 – Early Trials
alectinib
Sensitive
:
C3
alectinib
Sensitive: C3 – Early Trials
alectinib
Sensitive
:
C3
KIF5B-RET fusion
Lung Cancer
KIF5B-RET fusion
Lung Cancer
alectinib
Resistant: C3 – Early Trials
alectinib
Resistant
:
C3
alectinib
Resistant: C3 – Early Trials
alectinib
Resistant
:
C3
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
alectinib
Sensitive: C3 – Early Trials
alectinib
Sensitive
:
C3
alectinib
Sensitive: C3 – Early Trials
alectinib
Sensitive
:
C3
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
crizotinib + alectinib
Sensitive: C3 – Early Trials
crizotinib + alectinib
Sensitive
:
C3
crizotinib + alectinib
Sensitive: C3 – Early Trials
crizotinib + alectinib
Sensitive
:
C3
STRN-ALK fusion + MET amplification
Non Small Cell Lung Cancer
STRN-ALK fusion + MET amplification
Non Small Cell Lung Cancer
alectinib
Sensitive: C3 – Early Trials
alectinib
Sensitive
:
C3
alectinib
Sensitive: C3 – Early Trials
alectinib
Sensitive
:
C3
LMO7-ALK fusion
Non Small Cell Lung Cancer
LMO7-ALK fusion
Non Small Cell Lung Cancer
alectinib
Resistant: C3 – Early Trials
alectinib
Resistant
:
C3
alectinib
Resistant: C3 – Early Trials
alectinib
Resistant
:
C3
ALK mutation
Non Small Cell Lung Cancer
ALK mutation
Non Small Cell Lung Cancer
crizotinib + alectinib
Sensitive: C3 – Early Trials
crizotinib + alectinib
Sensitive
:
C3
crizotinib + alectinib
Sensitive: C3 – Early Trials
crizotinib + alectinib
Sensitive
:
C3
ALK rearrangement + TP53 wild-type
Non Small Cell Lung Cancer
ALK rearrangement + TP53 wild-type
Non Small Cell Lung Cancer
alectinib
Sensitive: C3 – Early Trials
alectinib
Sensitive
:
C3
alectinib
Sensitive: C3 – Early Trials
alectinib
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login